{"nctId":"NCT01734928","briefTitle":"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","startDateStruct":{"date":"2013-01-07","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":559,"armGroups":[{"label":"Pomalidomide, Bortezomib and Low Dose Dexamethasone","type":"EXPERIMENTAL","interventionNames":["Drug: Pomalidomide","Drug: Bortezomib","Drug: Dexamethasone"]},{"label":"Bortezomib and Low Dose Dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bortezomib","Drug: Dexamethasone"]}],"interventions":[{"name":"Pomalidomide","otherNames":["Oral Pomalidomide","CC-4047"]},{"name":"Bortezomib","otherNames":["Velcade"]},{"name":"Dexamethasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be ≥ 18 years at the time of signing informed consent.\n* Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis.\n* Must have had at least 1 but no greater than 3 prior anti-myeloma regimens.\n* Must have documented disease progression during or after their last anti-myeloma therapy.\n* All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.\n\nExclusion Criteria:\n\n* Documented progressive disease during therapy or within 60 days of the last dose of a bortezomib-containing therapy under the 1.3 mg/m\\^2 dose twice weekly dosing schedule.\n* Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization.\n* Non-secretory multiple myeloma.\n* Subjects with severe renal impairment requiring dialysis.\n* Previous therapy with pomalidomide.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival by Independent Response Adjudication Committee (IRAC)","description":"Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death.\n\nProgressive Disease is defined as an Increase of ≥ 25% from nadir in:\n\n* Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g\n* Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours)\n* In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \\> 100 mg/dL.\n* Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h\n* Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.20","spread":null},{"groupId":"OG001","value":"7.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) is calculated as the time from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.58","spread":null},{"groupId":"OG001","value":"31.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate by Independent Response Adjudication Committee (IRAC)","description":"The ORR together with the relative proportions in each response category (ie, stringent CR \\[sCR\\], CR, very good PR \\[VGPR\\], PR, SD, and PD) by treatment using the IMWG criteria will be examined.\n\nComplete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow\n\nSCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\n\nVGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \\< 100 mg per 24 hours\n\nPR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg per 24 hours\n\nProgressive Disease: Please refer to Primary outcome measure for definition\n\nSD: Not meeting criteria for CR, VGPR, PR, or progressive disease","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response by Independent Response Adjudication Committee (IRAC)","description":"Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first.\n\nComplete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow\n\nSCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\n\nVGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \\< 100 mg per 24 hours\n\nPR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg per 24 hours\n\nProgressive Disease: Please refer to Primary outcome measure for definition\n\nSD: Not meeting criteria for CR, VGPR, PR, or progressive disease","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.70","spread":null},{"groupId":"OG001","value":"10.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)","description":"Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"194","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)","description":"Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":177,"n":278},"commonTop":["Peripheral sensory neuropathy","Thrombocytopenia","Diarrhoea","Neutropenia","Fatigue"]}}}